What you didn’t see today.
Let’s be honest here did anyone really think the results released by Novo Nordisk wouldn’t be great. Sales of obesity drugs continue to increase; the company is working on meeting demand and the pipeline looks very promising. Just as an FYI we’re going to hear the same thing when Lilly reports results next week. These two longtime rivals first with insulin now with GLP-1’s are at it again and making boatloads of money while they compete.
While Novo is getting all the attention a few items also took place that largely went unnoticed.
First Dexcom . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.